ArticleThe American journal of tropical medicine and hygiene2025
Significant Reduction in Seroprevalence of Antibodies Against Hepatitis A across Thailand, 2024.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving trends in hepatitis A epidemiology: Shifting patterns, emerging risks, and future strategies.World journal of virology · 2025Review
- Current Epidemiological Trends and Public Health Challenges of Hepatitis A Virus Infection in Thailand.The American journal of tropical medicine and hygiene · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) is an RNA virus that causes acute hepatitis and is transmitted via the fecal-oral route. It has historically been highly endemic in Thailand, where most children develop lifelong immunity after infection. Economic development and improved sanitation have reduced HAV transmission, but immunity levels have declined, raising concerns about potential future outbreaks. This study aims to assess the seroprevalence of HAV antibodies in Thailand in 2024, 10 years after the last national survey in 2014, and to evaluate current immunity levels to inform public health strategies. A cross-sectional study was conducted in a population aged 6 months to 80 years across Thailand's geographic regions. A total of 4,312 serum samples were tested for anti-HAV antibodies using the chemiluminescent microparticle immunoassay. The seroprevalence data were compared with findings from previous surveys in 2004 and 2014. The study showed a significant decline in population immunity to HAV, with the age at which 50% of individuals had antibodies increasing from 36 in 2004 to 42 in 2014, and to 47 years in 2024. A majority of the population remained susceptible to HAV, particularly among younger age groups. Thailand has transitioned to low HAV endemicity, with a large proportion of the population lacking immunity. Despite the absence of significant outbreaks in recent decades, the risk of future outbreaks remains, particularly from imported cases. Enhanced surveillance and vaccination strategies are necessary to prevent future HAV transmission and manage public health risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.